IL-17A has been extensively studied in autoantibody-mediated disease and classical chronic inflammatory diseases, such as neuromyelitis optica (NMO), rheumatoid arthritis, ankylosing spondylitis, and psoriasis [44,45]. Here, IL17A is linked to ankylosing spondylitis.